OUR APPROACH
We are a diverse and passionate team with a united vision of making a true and lasting difference to the lives of anaphylaxis sufferers worldwide. We believe in our product and the positive impact it will have in revolutionising the way anaphylaxis is treated.
THE PROBLEM
Est. 156 million people ae affected by anaphylaxis
60% don’t carry their EpiPen
30-45% who do carry refuse to administer
Current solutions are unstable in harsh environments
“Anaphylaxis is a severe, potentially life-threatening allergic reaction that requires immediate treatment with adrenaline (epinephrine). Current treatments like traditional adrenaline injectors, despite their effectiveness, face significant practical issues that limit their use. Patients report issues such as bulkiness of the device, short shelf life, temperature susceptibility, and the hesitation to use it due to needle phobia. Consequently, many patients are either reluctant to carry or use their adrenaline injector, leading to increased risk during an anaphylaxis."
Allergy Specialist
OUR SOLUTION
“Our product provides a holistic solution, solving all identified problems with current adrenaline delivery systems. Our solution will minimise delayed or absent administration of adrenaline and improve patients' quality of life.”
Liam Mahony
Adracard CEO & Anaphylaxis sufferer
Accessible
Easy to use
Economical
OUR TEAM
We combine lived experience of anaphylaxis with decades of drug-device expertise
Our team has already taken multiple drug delivery products from concept to US market
Dr. Liam Mahony
Founder & CEO
Lachlan Timms
Founder & CTO
Dr. Tony Flint
Head of Quality and Reg
Dr. Colin Sheldrake
Head of Product Development
ADVISORY BOARD
Dr. Eddie French
Ex-Head of Device Drug Delivery, Pfizer
Dr. Narinder Singh
ENT
Dr. Paul Wynne
Organic chemist & drug project manager
Eddie Walker
IP attorney for FB Rice
Emma Cleary
Director
Device Technologies
In Memoriam
Enterprise Professor Dr. Katie Allen
PROUDLY SUPPORTED BY
